Mountain View
Seeking Alpha
ViiV's Dovato as effective as Gilead's Biktarvy for HIV but with less weight gain
A head-to-head trial found that ViiV Healthcare's HIV med Dovato (dolutegravir/lamivudine) is as effective as Gilead Sciences' (NASDAQ:GILD) Biktarvy (bictegravir/emtricitabine/tenofovir) but with less weight gain. The PASO DOBLE trial enrolled 553 people with HIV who were randomized to receive one of the two treatments. After 48 weeks, Dovato was found...
O'Keefe Stevens Advisory Q2 2024 Investor Letter
Continued hopes of near-term rate cuts drove a 3.9% gain in the S&P 500 in Q2. The S&P equal-weighted index again lagged its market cap-weighted counterpart, down ~2% in the quarter, displaying the concentrated and top-heavy nature of the rally. We initiated two new positions during the quarter: Alibaba and...
Abercrombie & Fitch: Retail Rocket Ship Continues To Defy Gravity
Abercrombie & Fitch has engineered a successful turnaround, rewarding its investors. ANF investors have jumped onto the bandwagon, powering the stock to a 1Y total return of over 320%. Abercrombie: Defying Gravity With Its Turnaround. Abercrombie & Fitch Co. (NYSE:ANF) is a leading retail lifestyle company that has transformed its...
FDA grants fast track status to BioAlta's ozuriftamab vedotin
BioAlta (NASDAQ:BCAB) said the FDA has granted Fast Track Designation to its antibody drug conjugate ozuriftamab vedotin in the treatment of certain patients with squamous cell carcinoma of the head and neck, or SCCHN. The agency granted the designation for the treatment of patients with recurrent or metastatic SCCHN with...
U.K. regulators approve Wegovy for prevention of cardiac events
U.K. regulators have approved Novo Nordisk’s (NVO) semaglutide, also known as Wegovy, for the prevention of cardiac events in obese or overweight adults with cardiovascular disease. Semaglutide is already approved in the U.K. for the treatment of obesity and diabetes. Novo (NVO) markets semaglutide for weight loss under the...
Artisan Mid Cap Value Fund Q2 2024 Commentary
Following broad market participation that drove US equities higher in late 2023 and early 2024, markets narrowed in Q2, with a handful of mega-cap technology names lifting the S&P 500 Index to all-time highs on the AI FOMO trade. Given the meaningful outperformance by large-cap growth stocks, which drove the...
SentinelOne: 3 Reasons Why Now Makes Sense
I anticipate more businesses will switch to SentinelOne, Inc. from CrowdStrike as contracts and sales cycles mature. I believe SentinelOne's recent 31% CAGR guidance is now a conservative and attainable benchmark. Investment Thesis. SentinelOne, Inc. (NYSE:S) is a buy on many fronts. Indeed, here I highlight 3 succinct reasons why...
Are There Canadian Market Opportunities Hiding In Plain Sight?
Canadian stocks to watch in H2 of 2024. Why the Canadian financial sector may provide opportunities. Much has been said about the excitement around AI and rally in U.S. equities. Michael O’Brien, Managing Director and Head of the Core Canadian Equity Team at TD Asset Management, says while much of the attention has been on big tech, there are some Canadian stocks that may be worth a closer look.
CrossingBridge Advisors Q2 2024 Commentary
In today’s fixed income market, we find ourselves in a similar position, “between a rock and a hard place”. Tight credit spreads as well as the inverted yield curve and elevated uncertainty make for a very challenging outlook. After a brief discussion of the tightening of credit...
Mesoblast stock climbs 7% on FDA acceptance of Ryoncil application
Mesoblast (NASDAQ:MESO) stock rose 7% in morning trading Tuesday after the company said the FDA has accepted its resubmitted Biologics License Application for its therapy Ryoncil for the treatment of children with steroid-refractory acute graft versus host disease, or SR-aGVHD. The agency’s target action date for the application is Jan....
Inflation Forces Quick Service Restaurants To Innovate Amid Less Foot Traffic
Fast food prices have risen twice the total inflation rate in the last ten years, with McDonald's, Popeyes, and Taco Bell leading the price increases. Eight in ten Americans consider fast food a luxury, leading to low traffic and stagnant same-store sales in 2024. Introduction. Much has been said about...
Newmont Q2 preview: Divestment plan in focus as earnings expected to rise
Top gold miner Newmont (NYSE:NEM) is expected to report a strong growth in second-quarter earnings when it reports on Wednesday, before market open, riding on a significant surge in gold prices and a favorable macro environment. The consensus EPS estimate is $0.62 (+87.9% Y/Y) and the consensus revenue estimate is...
Technip Energies: LNG Specialist Trading At A 9% FCF Yield
Technip Energies (OTCPK:THNPY) is a French engineering and technology company that focuses on applications in the energy transition space. It is a leader when it comes to LNG (where it has designed and built about 20% of the current global LNG production capacity), hydrogen, and ethylene-related construction jobs while it is also increasing its importance and improving its reputation in the CO2 management and blue and green hydrogen subsectors. The company is active in 35 countries and employs approximately 15,000 people.
4 Positives For Johnson & Johnson
Johnson & Johnson might be the worst performing big pharma stock YTD, but there's upside possible for it in the remainder of 2024. Revenue growth guidance was upgraded and even with a downgrade in EPS guidance, the number is still expected to see a YoY increase. Among the big five...
Canada's Economy Feels Like A Recession
Canada’s June unemployment rate of 6.4% was up 160 basis points from the cycle low of 4.8% in June 2022. Since the 1970s, Canada has never had this trough-to-peak rise in the unemployment rate without the economy going through a recession. Canada’s June unemployment rate of 6.4% was up...
Next Century Growth Investors Q2 2024 Commentary
In the second quarter of 2024, equity markets were a mixed bag. Overall, large cap stocks continue to outperform small cap stocks, a trend that has persisted for the better part of the last decade. While the timing of the first rate cut is uncertain, the Fed is leaning toward...
Northeast Bank: Good Growth Prospects
Northeast Bank offers potential for above-average returns with a unique business model combining organic growth and purchasing loans at discounts. Anticipation of interest rate cuts is high, which could benefit banks like NBN and Esquire Financial Holdings in the future. I believe a lot of potential for above-average returns and...
Walgreens awarded $25M in federal funds for COVID vaccine trial
Walgreens (NASDAQ:WBA) announced Tuesday that the U.S. government has awarded a project worth up to $25M to conduct a Phase 4 clinical study to assess the effectiveness of FDA-authorized COVID-19 vaccines. As part of the program, some Walgreens (WBA) community pharmacies will be used as clinical trial sites to assess,...
Airbnb: Buy This Stock While It's Cooling Down Pre-Earnings
Airbnb's stock has cooled off since March, presenting a strong buying opportunity ahead of the Q2 earnings cycle. New features like Icons and group trip organization are distinguishing Airbnb from competitors and expanding its market appeal. While the S&P 500 has continued to race toward new all-time highs powered by...
Seeking Alpha
153K+
Posts
1M+
Views
Seeking Alpha is an industry leader in mining the wisdom of the crowds for insights on every topic of interest to investors. Our editors curate investing news and analysis from a network of stock analysts, traders, economists, academics, financial advisers and industry experts — all who engage in our community.
It’s essential to note our commitment to transparency:
Our Terms of Use acknowledge that our services may not always be error-free, and our Community Standards emphasize our discretion in enforcing policies. As a platform hosting over 100,000 pieces of content published daily, we cannot pre-vet content, but we strive to foster a dynamic environment for free expression and robust discourse through safety guardrails of human and AI moderation.